Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Michel Bazinet; Victor Pântea; Valentin Cebotarescu; Lilia Cojuhari; Pavlina Jimbei; Jeffrey Albrecht; Peter Schmid; Frédéric Le Gal; Emmanuel Gordien; Adalbert Krawczyk; Hrvoje Mijočević; Hadi Karimzadeh; Michael Roggendorf; Andrew Vaillant

doi:10.1016/s2468-1253(17)30288-1

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(17)30288-1 ◽

2017 ◽

Vol 2 (12) ◽

pp. 877-889 ◽

Cited By ~ 74

Author(s):

Michel Bazinet ◽

Victor Pântea ◽

Valentin Cebotarescu ◽

Lilia Cojuhari ◽

Pavlina Jimbei ◽

...

Keyword(s):

Pegylated Interferon ◽

Phase 2 ◽

Open Label ◽

Hepatitis D ◽

Phase 2 Trial ◽

Chronic Hepatitis B Virus ◽

B Virus ◽

Open Label Phase ◽

Treatment Naïve ◽

Pegylated Interferon Alfa

Download Full-text

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

The Lancet ◽

10.1016/s0140-6736(13)60247-0 ◽

2013 ◽

Vol 381 (9883) ◽

pp. 2100-2107 ◽

Cited By ~ 203

Author(s):

Kris V Kowdley ◽

Eric Lawitz ◽

Israel Crespo ◽

Tarek Hassanein ◽

Mitchell N Davis ◽

...

Keyword(s):

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Pegylated Interferon Alfa

Download Full-text

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30030-3 ◽

2017 ◽

Vol 4 (4) ◽

pp. e165-e175 ◽

Cited By ~ 48

Author(s):

Lucia Masarova ◽

Keyur P Patel ◽

Kate J Newberry ◽

Jorge Cortes ◽

Gautam Borthakur ◽

...

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

Polycythaemia Vera ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Pegylated Interferon Alfa ◽

Post Hoc

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Cited By ~ 1

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Hepatitis C Infection ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Ns3 Protease

Download Full-text

Faculty of 1000 evaluation for Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020710.793480337 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

Pegylated Interferon Alfa

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Download Full-text

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30480-8 ◽

2019 ◽

Vol 19 (1) ◽

pp. 46-55 ◽

Cited By ~ 9

Author(s):

Jung-Kyu Lee ◽

Ji Yeon Lee ◽

Deog Kyeom Kim ◽

Ho Il Yoon ◽

Ina Jeong ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Phase 2 ◽

Open Label ◽

Intensive Phase ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text